Skip to content
Screener

Amphastar Pharmaceuticals AMPH Finished Pharmaceutical Products — Advertising Expense

Similar metrics at other companies

Nathan's Famous logo
NATHProduct Licensing — Advertising Expense
$0
Nathan's Famous logo
NATHBranded Product Program — Advertising Expense
$0
Oil-Dri Corporation of America logo
ODCBusiness to Business Products — Advertising Expense
$169K-36.5%
Oil-Dri Corporation of America logo
ODCRetail and Wholesale Products — Advertising Expense
$1.55M-12.3%
Restoration Hardware logo
RHRH — Advertising Expense
$51.18M+5.0%
Restoration Hardware logo
RHWaterworks — Advertising Expense
$938K+43.2%

Other financials

Income statement

See full
Revenue$183.9M+5.4%
Gross profit$93.5M+8.1%
Operating income$39.7M-5.8%
Net income$30.3M-2.2%
EPS (diluted)$0.67+4.7%

Balance sheet

See full
Cash & equivalents$223.6M+19.1%
Total debt$688.5M+5.0%
Total equity$445.5M
Total assets$1.7B+8.0%

Cash flow

See full
Operating cash flow$51.3M+44.2%
CapEx$8.6M-18.7%
Free cash flow$42.7M+70.7%

Valuation

See full
Market cap$863.95M-32.1%
Enterprise value$1.33B-23.6%
P/E11×+1.6×
P/S1.2×-0.6×

Profitability

See full
Gross margin47.7%-2.2pp
Operating margin15.7%-9.5pp
Net margin10.8%-7.9pp
FCF margin20.9%+5.4pp

Returns & leverage

See full
Return on equity14.7%
Debt / equity0.2×
Current ratio2.4×-0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AdvertisingExpense.

The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:50 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001297184-26-000047

Advertising expenses, primarily associated with Primatene MIST®, are recorded as they are incurred, except for expenses related to the development of a major commercial or media campaign, which are expensed in the period in which the commercial or campaign is first presented, and are reflected as a component of selling, distribution and marketing in the Company’s condensed consolidated statements of operations. For the three and six months ended June 30, 2026, advertising expenses were $3.3 million and $5.8 million, respectively. For the three and six months ended June 30, 2025, advertising expenses were $2.5 million and $5.5 million, respectively.

Item 1. Financial Statements (unaudited)

FAQ

What is Amphastar Pharmaceuticals's finished pharmaceutical products — advertising expense?
Amphastar Pharmaceuticals (AMPH) reported finished pharmaceutical products — advertising expense of $3.3M in Q2 2026.
How has Amphastar Pharmaceuticals's finished pharmaceutical products — advertising expense changed year-over-year?
Amphastar Pharmaceuticals's finished pharmaceutical products — advertising expense increased by 32.0% year-over-year, from $2.5M to $3.3M.
What is the long-term trend for Amphastar Pharmaceuticals's finished pharmaceutical products — advertising expense?
Over 2 years (2021 to 2023), Amphastar Pharmaceuticals's finished pharmaceutical products — advertising expense has grown at a 13.3% compound annual growth rate (CAGR), from $8.1M to $10.4M.
What does finished pharmaceutical products — advertising expense mean?
This metric tracks the total costs incurred for marketing, promotional activities, and advertising campaigns specifically allocated to the finished pharmaceutical products segment. It measures the company's investment in brand awareness and market penetration to support the commercialization of its product offerings.

Ask your AI about Amphastar Pharmaceuticals's finished pharmaceutical products — advertising expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude